Other Species / Isoforms
  FMIP (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S5-p
___MSSEssKKRKPK
Upstream
Downstream
1 0
Effects on Modified Protein
  • intracellular localization
Kinase, in vitro:
  • PKCA (human)
Putative in vivo kinases:
  • PKCA (human)
Treatment
  • phorbol_ester
FMIP (human) ___MSSEssKKRKPK S5-p
FMIP (mouse) ___MSSESSKKRKPK S5
FMIP (rat) ___MSSESSKKRKPK S5
S6-p
__MSSEssKKRKPKV
Upstream
Downstream
1 0
Effects on Modified Protein
  • intracellular localization
Kinase, in vitro:
  • PKCA (human)
Putative in vivo kinases:
  • PKCA (human)
Treatment
  • phorbol_ester
FMIP (human) __MSSEssKKRKPKV S6-p
FMIP (mouse) __MSSESSKKRKPKV S6
FMIP (rat) __MSSESSKKRKPKV S6
S16-p
RKPKVIRsDGAPAEG
Upstream
0 5
Treatment
  • nocodazole
FMIP (human) RKPKVIRsDGAPAEG S16-p
FMIP (mouse) RKPKVIRsDGtPTEG S16-p
FMIP (rat) RKPKVIRSDGTPTEG S16
A19
KVIRsDGAPAEGkRN
0 3
FMIP (human) KVIRsDGAPAEGkRN A19
FMIP (mouse) KVIRsDGtPTEGkRN T19-p
FMIP (rat) KVIRSDGTPTEGkRN T19
K24-ac
DGAPAEGkRNRsDtE
0 70
FMIP (human) DGAPAEGkRNRsDtE K24-ac
FMIP (mouse) DGtPTEGkRNRsDTE K24-ac
FMIP (rat) DGTPTEGkRNRSDTE K24-ac
S28-p
AEGkRNRsDtEQEGK
0 69
FMIP (human) AEGkRNRsDtEQEGK S28-p
FMIP (mouse) TEGkRNRsDTEQEGK S28-p
FMIP (rat) TEGkRNRSDTEQEGR S28
T30-p
GkRNRsDtEQEGKYy
0 65
FMIP (human) GkRNRsDtEQEGKYy T30-p
FMIP (mouse) GkRNRsDTEQEGKYY T30
FMIP (rat) GkRNRSDTEQEGRYY T30
Y37-p
tEQEGKYySEEAEVD
0 1
FMIP (human) tEQEGKYySEEAEVD Y37-p
FMIP (mouse) TEQEGKYYSEEAEVD Y37
FMIP (rat) TEQEGRYYSEEAEVD Y37
K56-ub
GRDYELYkYTCQELQ
0 1
FMIP (human) GRDYELYkYTCQELQ K56-ub
FMIP (mouse) GRDYELYKYTCQELQ K56
FMIP (rat) GRDYELYKYTCQELQ K56
K146-ub
HLQKEITkCLEFKSK
0 1
FMIP (human) HLQKEITkCLEFKSK K146-ub
FMIP (mouse) HLQKEITKCLEFKSK K146
FMIP (rat) HLQKEITKCLEFKSK K146
K175-ub
EAPPDISkAEVTMGD
0 1
FMIP (human) EAPPDISkAEVTMGD K175-ub
FMIP (mouse) EAPPSISKAEITMGD K175
FMIP (rat) EAPPNISKAEITMGD K175
K204
QRKRLAEKYRECLsN
0 2
FMIP (human) QRKRLAEKYRECLsN K204
FMIP (mouse) QRKRLAEkYRECLSN K204-ac
FMIP (rat) QRKRLAEKYRECLSN K204
S210-p
EKYRECLsNKEKILk
0 1
FMIP (human) EKYRECLsNKEKILk S210-p
FMIP (mouse) EkYRECLSNKEKILK S210
FMIP (rat) EKYRECLSNKEKILK S210
K217-ub
sNKEKILkEIEVKKE
0 1
FMIP (human) sNKEKILkEIEVKKE K217-ub
FMIP (mouse) SNKEKILKEIEVKRD K217
FMIP (rat) SNKEKILKEIEVKKE K217
Y225-p
EIEVKKEyLSSLQPR
Upstream
Downstream
2 1
Effects on Modified Protein
  • intracellular localization
  • molecular association, regulation
Effects on Biological Processes:
  • cell motility, altered
  • signaling pathway regulation
  • translation, altered
Putative in vivo kinases:
  • PDGFRB (human)
  • Src (human)
Regulatory protein:
  • BCR-ABL1 (human)
  • NPM-ALK (human)
  • PDGFRB (human)
  • Tel (human)
Treatment
  • CXCL12
  • dasatinib
  • etoposide
  • H2O2
  • imatinib
  • KU-55933
  • LY294002
  • nilotinib
  • ruxolitinib
  • SU6656
  • U0126
FMIP (human) EIEVKKEyLSSLQPR Y225-p
FMIP (mouse) EIEVKRDYLSSLQPR Y225
FMIP (rat) EIEVKKEYLSSLQPR Y225
S235
SLQPRLNSIMQASLP
0 1
FMIP (human) SLQPRLNSIMQASLP S235
FMIP (mouse) SLQPRLNsIMQAsLP S235-p
FMIP (rat) SLQPRLNSIMQASLP S235
S240
LNSIMQASLPVQEYL
0 1
FMIP (human) LNSIMQASLPVQEYL S240
FMIP (mouse) LNsIMQAsLPVQEYL S240-p
FMIP (rat) LNSIMQASLPVQEYL S240
S293-p
LSVAIEGsVDEAKAL
0 2
FMIP (human) LSVAIEGsVDEAKAL S293-p
FMIP (mouse) LSVAIEGSVDEAKAL S293
FMIP (rat) LSVAIEGSVDEAKAL S293
S307-p
LFKPPEDsQDDEsDs
Upstream
1 51
Kinase, in vitro:
  • ATM (human)
Treatment
  • etoposide
  • nocodazole
FMIP (human) LFKPPEDsQDDEsDs S307-p
FMIP (mouse) LFKPPEDsQDDEsDs S307-p
FMIP (rat) LFKPPEDSQDDESDs S307
S312-p
EDsQDDEsDsDAEEE
Upstream
1 81
Kinase, in vitro:
  • ATM (human)
Treatment
  • etoposide
  • nocodazole
FMIP (human) EDsQDDEsDsDAEEE S312-p
FMIP (mouse) EDsQDDEsDsDAEEE S312-p
FMIP (rat) EDSQDDESDsDAEEE S312
S314-p
sQDDEsDsDAEEEQt
Upstream
1 82
Kinase, in vitro:
  • ATM (human)
Treatment
  • etoposide
  • nocodazole
FMIP (human) sQDDEsDsDAEEEQt S314-p
FMIP (mouse) sQDDEsDsDAEEEQT S314-p
FMIP (rat) SQDDESDsDAEEEQT S314-p
T321-p
sDAEEEQtTKRRRPt
0 1
FMIP (human) sDAEEEQtTKRRRPt T321-p
FMIP (mouse) sDAEEEQTtKRRRPt T321
FMIP (rat) sDAEEEQTTRRRPtL T321
T322
DAEEEQtTKRRRPtL
0 1
FMIP (human) DAEEEQtTKRRRPtL T322
FMIP (mouse) DAEEEQTtKRRRPtL T322-p
FMIP (rat) DAEEEQTTRRRPtLG T322
T328-p
tTKRRRPtLGVQLDD
Upstream
0 722
Treatment
  • EGF
  • gefitinib
  • selumetinib
  • U0126
  • vemurafenib
FMIP (human) tTKRRRPtLGVQLDD T328-p
FMIP (mouse) TtKRRRPtLGVQLDD T328-p
FMIP (rat) QTTRRRPtLGVQLDD T327-p
K336
LGVQLDDKRKEMLKR
0 1
FMIP (human) LGVQLDDKRKEMLKR K336
FMIP (mouse) LGVQLDDkRkEMLKR K336-ac
FMIP (rat) LGVQLDDKRKEMLKR K335
K336-ub
LGVQLDDkRKEMLKR
0 1
FMIP (human) LGVQLDDkRKEMLKR K336-ub
FMIP (mouse) LGVQLDDKRkEMLKR K336
FMIP (rat) LGVQLDDKRKEMLKR K335
K338
VQLDDkRKEMLKRHP
0 1
FMIP (human) VQLDDkRKEMLKRHP K338
FMIP (mouse) VQLDDkRkEMLKRHP K338-ac
FMIP (rat) VQLDDKRKEMLKRHP K337
S347-p
MLKRHPLsVMLDLKC
0 2
FMIP (human) MLKRHPLsVMLDLKC S347-p
FMIP (mouse) MLKRHPLSVLLDLKC S347
FMIP (rat) MLKRHPLSVLLDLKC S346
K412-ub
YPGDHGKkTPNPANQ
0 1
FMIP (human) YPGDHGKkTPNPANQ K412-ub
FMIP (mouse) YPGDHGKKTPNPANQ K412
FMIP (rat) YPGDHGKKTPNPANQ K411
Y420-p
TPNPANQyQFDKVGI
0 1
FMIP (human) TPNPANQyQFDKVGI Y420-p
FMIP (mouse) TPNPANQYQFDkVGI Y420
FMIP (rat) TPNPANQYQFDKVGI Y419
K424
ANQyQFDKVGILTLS
0 1
FMIP (human) ANQyQFDKVGILTLS K424
FMIP (mouse) ANQYQFDkVGILTLR K424-ac
FMIP (rat) ANQYQFDKVGILTLR K423
K477-ub
SHMETTMkLLKTRVQ
0 1
FMIP (human) SHMETTMkLLKTRVQ K477-ub
FMIP (mouse) SHMETTMKLLKTRVQ K477
FMIP (rat) SHMETTMKLLKTRVQ K476
K514-ub
CQYLFPAkVVSRLVK
0 1
FMIP (human) CQYLFPAkVVSRLVK K514-ub
FMIP (mouse) CQDLFPAKVVSRLVK K514
FMIP (rat) CQYLFPAKVVSRLVK K513